is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Market research – including Pharmapack country rankings, innovation and sustainability indices – and expert input.
Pharmapack will be organised in accordance with Informa’s AllSecure health and safety standard. As the world’s leading events’ organiser, Informa has developed a detailed set of enhanced measures to provide the highest levels of hygiene and safety at its events, providing everyone with reassurance and confidence they are participating in a safe and controlled environment. Read more.
Under the gradual re-opening strategy confirmed by President Emmanuel Macron, trade shows and exhibitions will return in France from June 9th onwards. The announcement enables Europe’s premier pharma packaging and drug delivery event to return on-site for the first time since February 2020. The event will be held in a hybrid format – featuring a two-week online content programme and a three day in-person event – empowering the industry with greater opportunities to drive forward innovation and partnerships.
Here at Pharmapack, we understand the importance of meeting face-to-face with your peers and potential business partners - in 2021 we want to make sure you get the chance to do just that.
We regularly keep in touch with our stakeholders and based on their feedback, we have decided to postpone our show until 13th – 14th October 2021, so that we can continue to provide the same service and deliver an event in line with what you’ve come to expect from Pharmapack Europe.
Nobody likes to be out of touch, and in these times when it’s more difficult to come together and meet our peers in person, we’ve created The Pharmapack Review newsletter to ensure you stay connected and in touch with the industry’s latest happenings.
In this podcast, recorded live on-site at Pharmapack Europe 2020, we speak with Aurelio Arias, Senior Consultant - Thought Leadership at IQVIA, on his outlook for biologics packaging market. How can device manufacturers gain a competitive advantage in the design of drug delivery devices for biologics through patient experience and adherence? What’s the outlook for emerging cell and gene therapies?
Developers of digital health tools designed to improve adherence to medicines need to make behavioural science the cornerstone of their strategy if they are to keep patients engaged and motivated, according to Paul Upham, Head of Smart Devices at Roche/Genentech.
Pharmaceutical companies need to change their mindset and focus more on delivering extra value from smart packaging rather than reducing the cost of their packaging operation, according to Alex Cole, senior strategic marketing manager at CPI.
The Pharmapack team has been working hard to actively monitor the COVID-19 situation and as it stands, we do not plan to postpone or cancel our next event, which will take place from 27-28 January 2021. The wellbeing of our community remains our top priority and as an Organized Gathering we will be implementing the World Health Organization’s recommended measures for gatherings, as well as following the steps advised by local health authorities.
The ability of pharmaceutical packaging to add value and improve the experience for both patients and healthcare professionals was a core theme at Pharmapack Europe 2020, with the emphasis on how the industry can identify opportunities via technological advancements in smart packaging.
Wittenburg did support the "Impact of alternative materials to plasticized PVC infusion tubings on drug sorption and plasticizer release” study conducted by the ClermontFerrand University Hospital Center.
By Yasemin Karanis, Consultant, Thought Leadership, IQVIA.
The global pharmaceutical market is expected to exceed $1.5 trillion by 2023. However, the growth we see is decelerating. This is happening
even though there are more products being developed and launched and the level of innovation is high.
Pharmapack talks to Prof. Dr. Sigrid Saaler-Reinhardt, Director Corporate Project Management at Midas Pharma GmbH about the key challenges and innovations around injection devices and her expectations for Pharmapack 2020.
With the world’s attitude to tackling climate change arguably the global number one hot topic of 2019, the issue of sustainability is an emerging theme in pharmaceutical packaging.
Six trends are shaping the future of global pharmaceutical packaging, according to research and analysis from researchers at Pharmapack Europe. Their results, summarized below, are contained in “The Golden Age of Innovation Is Beginning: Drug Delivery and Packaging Report 2019.”
Paris, 19th August 2019: As predicted by the ‘European drug delivery and packaging’ report earlier this year, new data shows innovation in drug delivery is accelerating across Europe – with provisional findings from the Pharmapack Innovation Index (2020) showing that Switzerland has over taken Germany as Europe’s most innovative drug delivery market.
Suzhou Dialogue 2019 which is organized by China National Pharmaceutical Packaging Association (CNPPA) will be held on Sept.1-3 in Suzhou, China. The major objective of this forum is to promoting human health, improving patient experience during drug treatment and advancing development of pharmaceutical packaging/drug delivery device industry.
About the company: Merxin is a designer, developer and supplier of generic and customised drug delivery and medical device platforms.
Interviewee name: Phillipe Rogueda.
Job title: Chief Business Officer.
Pharmapack Europe (#PharmapackEU), announces the winners of the much heralded 2019 Pharmapack Awards. Due to the exceptional standard of entries, nine worthy winners were chosen across two categories: ‘Exhibitor Innovations’ and ‘Health Products’.
New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.